Ilika, Allergy Therapeutics, Ecora Royalties, EGT, Rockfire Resources, Bradda Head Lithium

Ilika, Allergy Therapeutics, Ecora Royalties, EGT, Rockfire Resources, Bradda Head Lithium

Wed, July 29, 2026 at 11:28 AM GMT+3

Ilika (AIM:IKA) says it's now a revenue-generating business, with initial royalties from its Stereax miniature solid-state batteries expected in its 2027 financial year. Releasing its 2026 results, the company said its larger Goliath battery is also attracting interest from defence and e-bike markets, including a collaboration with Brompton Bicycle.

Allergy Therapeutics (AIM:AGY) says revenue growth accelerated in its second half, with full-year revenue up 9% to £59.9 million. Double-digit growth is expected next year as Grassmuno enters its first full peak treatment season.

Ecora Royalties (LSE:ECOR) saw its quarterly portfolio contribution jump 61% to $19 million, driven by record cobalt receipts from Voisey's Bay. Net debt has fallen to $74.9 million and the company expects further deleveraging through the rest of 2026.

European Green Transition (AIM:EGT) says its wind services business is on track for £17-18 million in revenue this year after a strong first half. The company's repowering pipeline stands at 65 signed heads of terms across a 900-turbine customer base.

Rockfire Resources (LSE:ROCK) has returned its best drilling result yet at its Molaoi zinc deposit in Greece, with grades appearing to strengthen at depth. A new drilling rig is due to arrive in Athens in late September.

Bradda Head Lithium (AIM:BHL) has secured a drilling contractor for its Arizona lithium campaign, with the rig expected to mobilise by end of July. The programme targets a maiden resource estimate at Whistlejacket by the end of 2027.

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy